Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Probiotic Strain SNZ 1969
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing IBS...
Brand Name : SNZ 1969
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 29, 2022
Lead Product(s) : Probiotic Strain SNZ 1969
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lacticacid Bacillus
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : J.B.Chemicals & Pharmaceuticals
Deal Size : $84.0 million
Deal Type : Acquisition
JB Chemicals To Acquire Brands from Sanzyme For Rs, 628 Crore
Details : The probiotic portfolio includes Sporlac, which is the third-largest probiotics brand in India, and specialised products like Lobun used for delaying progression of chronic kidney disease and Oxalo, an alternate risk-free therapy to decalcify kidney ston...
Brand Name : Sporlac
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Lacticacid Bacillus
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : J.B.Chemicals & Pharmaceuticals
Deal Size : $84.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?